| Theme | Present Status of Chemoprevention for Tumors Derived from Digestive Diseases | |
|---|---|---|
| Title | Recent Progress and Future Perspectives on Digestive Tract Cancer Chemoprevention Research Using Experimental Animal Models | |
| Publish Date | 2008/11 | |
| Author | Takeshi Toyoda | Division of Oncological Pathology, Aichi Cancer Center Research Institute |
| Author | Masae Tatematsu | Division of Oncological Pathology, Aichi Cancer Center Research Institute |
| [ Summary ] | Experimental pathological studies using animal models have played an important role in the development of digestive tract cancer chemoprevention techniques. Chronic inflammation caused by Helicobacter pylori (H. pylori) or hepatitis B / C virus is known as a significant background cause of gastric or hepatic carcinogenesis. Eradication of H. pylori and interferon therapy are generally recommended as the major chemopreventive methods aimed at producing inhibitory effects on inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2)-selective inhibitors have been shown to exert suppressive effects on the progression of pre-cancerous lesions or early tumors and are expected to be applied in clinical use for the prevention of colorectal cancers and gastric adenocarcinomas after eradication of H. pylori. Research progress using animal models and future perspectives on chemoprevention of gastrointestinal cancer including that of the stomach, colon and liver are reviewed. | |